Briefings in Bioinformatics: Deep learning of pharmacogenomics resources: moving towards precision oncology

December 8, 2019

Yu-Chiao Chiu, Hung-I Harry Chen, Aparna Gorthi, Milad Mostavi, Siyuan Zheng, Yufei Huang, Yidong Chen Abstract The recent accumulation of cancer genomic data provides an opportunity to understand how a tumor’s genomic characteristics can affect its responses to drugs. This field, called pharmacogenomics, is a key area in the development of precision oncology. Deep learning (DL) methodology has emerged as a […]

Pediatric Blood & Cancer: Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children’s Oncology Group Phase 1 Consortium study (ADVL1411)

November 14, 2019

Abstract Purpose We conducted a phase 1/2 trial of the poly(ADP‐ribose) polymerase 1/2 inhibitor talazoparib in combination with low‐dose temozolomide (TMZ) to determine the dose‐limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetics of this combination in children with recurrent/refractory solid tumors; and to explore clinical activity in Ewing sarcoma (EWS) (NCT02116777). Methods Talazoparib […]

Aging Cell: mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging

November 6, 2019

Candice E. Van Skike, Ai‐Ling Lin, Raquel Roberts Burbank, Jonathan J. Halloran, Stephen F. Hernandez, James Cuvillier, Vanessa Y. Soto, Stacy A. Hussong, Jordan B. Jahrling, Martin A. Javors, Matthew J. Hart, Kathleen E. Fischer, Steven N. Austad, Veronica Galvan Abstract Cerebrovascular dysfunction and cognitive decline are highly prevalent in aging, but the mechanisms underlying these impairments are unclear. Cerebral blood flow decreases with aging and is […]

Neuro-Oncology Advances: PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling

November 5, 2019

Gangadhara R Sareddy 1 2, Uday P Pratap 1, Suryavathi Viswanadhapalli 1, Prabhakar Pitta Venkata 1, Binoj C Nair 1, Samaya Rajeshwari Krishnan 1, Siyuan Zheng 3 2, Andrea R Gilbert 4, Andrew J Brenner 5 2, Darrell W Brann 6, Ratna K Vadlamudi 1 2 Abstract Background: Glioblastoma (GBM) is a deadly neoplasm of the central nervous system. The molecular mechanisms and players that contribute to GBM development are incompletely understood. Methods: The expression of PELP1 in different grades of glioma […]

Journal of Immunology: Immune Sensing of Aeroallergen-Associated Double-Stranded RNA Triggers an IFN Response and Modulates Type 2 Lung Inflammation

November 1, 2019

Li She, Hamad H. Alanazi, Liping Yan, Yi Zou, Yilun Sun, Peter H. Dube, Edward G. Brooks, Gema D. Barrera, Zhao Lai, Yidong Chen, Yong Liu, Xin Zhang and Xiao-Dong Li Abstract The innate immune sensing of allergens or allergen-associated components regulates the development of type 2 inflammatory responses. However, the underlying molecular basis by which allergens or allergen-associated components are detected by innate immune receptors remains elusive. […]

MISSION MAGAZINE: Tiny molecule has big effect in childhood brain cancer (Rao Lab)

October 22, 2019

Sometimes small things make the biggest difference. A new study has found that a molecule thousands of times smaller than a gene is able to kill medulloblastoma, the most common childhood brain cancer. This tiny molecule, named MiR-584-5p, is quite efficient in its action. It sensitizes the cancer to chemotherapy and radiation, making it plausible […]

International Journal of Cancer: GD2‐directed CAR‐T cells in combination with HGF‐targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma

October 17, 2019

 Manish Charan Piyush Dravid Maren Cam Anthony Audino Amy C. Gross Michael A. Arnold Ryan D. Roberts Timothy P. Cripe Alexander Pertsemlidi Peter J. Houghton Hakan Cam Abstract Ewing sarcoma (EWS) is the second most common and aggressive type of metastatic bone tumor in adolescents and young adults. There is an unmet medical need to [...]

Human Mutation: Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1

October 8, 2019

Magdalena Koczkowska 1, Tom Callens 1, Yunjia Chen 1, Alicia Gomes 1, Alesha D Hicks 1, Angela Sharp 1, Eric Johns 1, Kim Armfield Uhas 2, Linlea Armstrong 3, Katherine Armstrong Bosanko 4, Dusica Babovic-Vuksanovic 5, Laura Baker 6, Donald G Basel 7, Mario Bengala 8, James T Bennett 9, Chelsea Chambers 10, Lola K Clarkson 11, Maurizio Clementi 12, Fanny M Cortés 13, Mitch Cunningham 14, M Daniela D’Agostino 15, Martin B Delatycki 16, Maria C Digilio 17, Laura Dosa 18, Silvia Esposito 19, Stephanie Fox 15, Mary-Louise Freckmann 20, Christine Fauth 21, Teresa Giugliano 22, Sandra Giustini 23, Allison Goetsch 24, Yael Goldberg 25, Robert S Greenwood 26, Cristin Griffis 7, Karen W Gripp 6, Punita Gupta 27, Eric Haan 28, Rachel K Hachen 29, Tamara L Haygarth 30, Concepción Hernández-Chico 31, Katelyn […]

Cancer Research: Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma

October 1, 2019

Xiaolong Li 1, Emmanuel Martinez-Ledesma 1 2, Chen Zhang 1, Feng Gao 1, Siyuan Zheng 1, Jie Ding 1, Shaofang Wu 1, Nghi Nguyen 3, Stephan C Clifford 3, Patrick Y Wen 4, Keith L Ligon 4, W K Alfred Yung 1, Dimpy Koul 5 Abstract PI3K-targeting therapy represents one of the most sought-after therapies for glioblastoma (GBM). Several small-molecule inhibitors have been evaluated in clinical trials, however, the emergence of resistance limits treatment potential. Here, we generated a patient-derived glioma […]